<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554693</url>
  </required_header>
  <id_info>
    <org_study_id>200544</org_study_id>
    <nct_id>NCT04554693</nct_id>
  </id_info>
  <brief_title>The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery</brief_title>
  <official_title>The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery: A Prospective, Randomized, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a difference in participant reported pain after&#xD;
      endometriosis surgery in participants given oral metronidazole versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, randomized, placebo-controlled trial. Women scheduled for&#xD;
      endometriosis surgery between 18-50 years of age will be invited to participate in the study.&#xD;
&#xD;
      Participants with surgically staged endometriosis will be randomized to the metronidazole&#xD;
      plus routine postoperative care arm or the placebo plus routine postoperative care arm.&#xD;
      Participants will take study or placebo drug for a total of 14 days.&#xD;
&#xD;
      Participants will complete surveys at baseline and postoperatively at 6 weeks, 6 months, 1&#xD;
      year, 2 years, 3 years, 4 years, and 5 years reporting intensity of endometriosis associated&#xD;
      pain on a visual analog scale, pregnancy outcomes, quality of life, and sexual health.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2027</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported pain persistence</measure>
    <time_frame>6 weeks postoperatively.</time_frame>
    <description>The outcome of binary, subject pain persistence, assessed as yes or no, will be compared between groups using the Fisher exact test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life scores</measure>
    <time_frame>1 year postoperatively.</time_frame>
    <description>Endometriosis Health Profile-5 on scale of 1-100 with higher scores meaning worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scores</measure>
    <time_frame>6 months postoperatively.</time_frame>
    <description>Endometriosis Health Profile-5 on scale of 1-100 with higher scores meaning worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scores</measure>
    <time_frame>6 weeks postoperatively.</time_frame>
    <description>Endometriosis Health Profile-5 on scale of 1-100 with higher scores meaning worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scores</measure>
    <time_frame>5 years postoperatively.</time_frame>
    <description>Endometriosis Health Profile-5 on scale of 1-100 with higher scores meaning worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual health</measure>
    <time_frame>6 weeks postoperatively.</time_frame>
    <description>Female sexual function index on a scale of 0-36 with higher scores meaning higher sexual dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual health</measure>
    <time_frame>6 months postoperatively.</time_frame>
    <description>Female sexual function index on a scale of 0-36 with higher scores meaning higher sexual dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual health</measure>
    <time_frame>1 year postoperatively.</time_frame>
    <description>Female sexual function index on a scale of 0-36 with higher scores meaning higher sexual dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual health</measure>
    <time_frame>5 year postoperatively.</time_frame>
    <description>Female sexual function index on a scale of 0-36 with higher scores meaning higher sexual dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported pain persistence</measure>
    <time_frame>1 year postoperatively.</time_frame>
    <description>The outcome of binary, subject pain persistence, assessed as yes or no, will be compared between groups using the Fisher exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported pain persistence</measure>
    <time_frame>6 months postoperatively.</time_frame>
    <description>The outcome of binary, subject pain persistence, assessed as yes or no, will be compared between groups using the Fisher exact test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fertility</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Number of pregnancies and miscarriages postoperatively will be compared</description>
  </other_outcome>
  <other_outcome>
    <measure>Fertility</measure>
    <time_frame>1 year postoperatively</time_frame>
    <description>Number of pregnancies and miscarriages postoperatively will be compared</description>
  </other_outcome>
  <other_outcome>
    <measure>Fertility</measure>
    <time_frame>5 years postoperatively</time_frame>
    <description>Number of pregnancies and miscarriages postoperatively will be compared</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Endometriosis</condition>
  <condition>Endometriosis-related Pain</condition>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metronidazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Halal and Kosher certified gelatin placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Oral</intervention_name>
    <description>250 mg oral three times a day for 14 days</description>
    <arm_group_label>Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Women aged 18-50 years old&#xD;
&#xD;
          -  Scheduled to undergo excision of endometriosis&#xD;
&#xD;
          -  Able to read and write in English and or Spanish&#xD;
&#xD;
          -  Pain score &gt; 2 on a 10 point visual analogue scale at baseline&#xD;
&#xD;
          -  Negative screening by CAGE questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to surgery&#xD;
&#xD;
          -  Contraindication to surgery&#xD;
&#xD;
          -  Known allergy to metronidazole&#xD;
&#xD;
          -  Known allergy to any component in gelatin placebo capsules&#xD;
&#xD;
          -  Scheduled hysterectomy&#xD;
&#xD;
          -  Endometriosis excision surgery within the last 3 months&#xD;
&#xD;
          -  Elevated serum creatinine&#xD;
&#xD;
          -  Abnormal liver function test greater than 2 times the normal&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Use of Disulfiram within the last 2 weeks&#xD;
&#xD;
          -  History of Cockayne syndrome&#xD;
&#xD;
          -  Inability to abstain from alcohol during the use of study drug&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female participants</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Resad Pasic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amira Quevedo, MD</last_name>
    <phone>5025884400</phone>
    <email>amira.quevedo@uoflhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Resad Pasic, MD, PhD</last_name>
    <phone>5025884400</phone>
    <email>resad.pasic@louisville.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AMIRA QUEVEDO, MD</last_name>
      <phone>502-588-4400</phone>
      <email>amira.quevedo@uoflhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012 Sep;98(3):511-9. doi: 10.1016/j.fertnstert.2012.06.029. Epub 2012 Jul 20. Review.</citation>
    <PMID>22819144</PMID>
  </reference>
  <reference>
    <citation>Working group of ESGE, ESHRE and WES, Saridogan E, Becker CM, Feki A, Grimbizis GF, Hummelshoj L, Keckstein J, Nisolle M, Tanos V, Ulrich UA, Vermeulen N, De Wilde RL. Recommendations for the Surgical Treatment of Endometriosis. Part 1: Ovarian Endometrioma. Hum Reprod Open. 2017 Dec 19;2017(4):hox016. doi: 10.1093/hropen/hox016. eCollection 2017.</citation>
    <PMID>31486802</PMID>
  </reference>
  <reference>
    <citation>Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010 Jul;116(1):223-236. doi: 10.1097/AOG.0b013e3181e8b073.</citation>
    <PMID>20567196</PMID>
  </reference>
  <reference>
    <citation>Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril. 2004 Oct;82(4):878-84.</citation>
    <PMID>15482763</PMID>
  </reference>
  <reference>
    <citation>Sutton CJ, Ewen SP, Whitelaw N, Haines P. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril. 1994 Oct;62(4):696-700.</citation>
    <PMID>7926075</PMID>
  </reference>
  <reference>
    <citation>Quaranta G, Sanguinetti M, Masucci L. Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases. Front Immunol. 2019 Nov 26;10:2653. doi: 10.3389/fimmu.2019.02653. eCollection 2019. Review.</citation>
    <PMID>31827467</PMID>
  </reference>
  <reference>
    <citation>Leonardi M, Hicks C, El-Assaad F, El-Omar E, Condous G. Endometriosis and the microbiome: a systematic review. BJOG. 2020 Jan;127(2):239-249. doi: 10.1111/1471-0528.15916. Epub 2019 Sep 19.</citation>
    <PMID>31454452</PMID>
  </reference>
  <reference>
    <citation>Chadchan SB, Cheng M, Parnell LA, Yin Y, Schriefer A, Mysorekar IU, Kommagani R. Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota. Hum Reprod. 2019 Jun 4;34(6):1106-1116. doi: 10.1093/humrep/dez041.</citation>
    <PMID>31037294</PMID>
  </reference>
  <reference>
    <citation>Simoens S, Hummelshoj L, D'Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum Reprod Update. 2007 Jul-Aug;13(4):395-404. Review.</citation>
    <PMID>17584822</PMID>
  </reference>
  <reference>
    <citation>Nogueira F, Sharghi S, Kuchler K, Lion T. Pathogenetic Impact of Bacterial-Fungal Interactions. Microorganisms. 2019 Oct 16;7(10). pii: E459. doi: 10.3390/microorganisms7100459. Review.</citation>
    <PMID>31623187</PMID>
  </reference>
  <reference>
    <citation>Mert I, Walther-Antonio M, Mariani A. Case for a role of the microbiome in gynecologic cancers: Clinician's perspective. J Obstet Gynaecol Res. 2018 Sep;44(9):1693-1704. doi: 10.1111/jog.13701. Epub 2018 Aug 2. Review.</citation>
    <PMID>30069974</PMID>
  </reference>
  <reference>
    <citation>Moloney RD, Johnson AC, O'Mahony SM, Dinan TG, Greenwood-Van Meerveld B, Cryan JF. Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome. CNS Neurosci Ther. 2016 Feb;22(2):102-17. doi: 10.1111/cns.12490. Epub 2015 Dec 10. Review.</citation>
    <PMID>26662472</PMID>
  </reference>
  <reference>
    <citation>Guo R, Chen LH, Xing C, Liu T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth. 2019 Nov;123(5):637-654. doi: 10.1016/j.bja.2019.07.026. Epub 2019 Sep 21. Review.</citation>
    <PMID>31551115</PMID>
  </reference>
  <reference>
    <citation>Glick LR, Sossenheimer PH, Ollech JE, Cohen RD, Hyman NH, Hurst RD, Rubin DT. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19;13(9):1158-1162. doi: 10.1093/ecco-jcc/jjz047.</citation>
    <PMID>30809655</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 5, 2020</study_first_submitted>
  <study_first_submitted_qc>September 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Resad Pasic</investigator_full_name>
    <investigator_title>Director, Fellowship in Advanced Gynecologic Endoscopy, Department of Obstetrics and Gynecology and Woman's Health, University of Louisville School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

